tetano
Editor, Senior Moderator
Sci Rep
. 2025 Jul 1;15(1):20900.
doi: 10.1038/s41598-025-05541-9. The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load
Petr Waldauf[SUP] 1 [/SUP], Ivana Jurisinova[SUP] 2 [/SUP], Eva Svobodova[SUP] 2 [/SUP], Michaela Diblickova[SUP] 2 [/SUP], Tomas Tencer[SUP] 1 [/SUP], Jan Zavora[SUP] 3 4 [/SUP], Gabriela Smela[SUP] 3 [/SUP], Lenka Kupidlovska[SUP] 3 [/SUP], Vaclava Adamkova[SUP] 3 [/SUP], Marta Fridrichova[SUP] 5 [/SUP], Karolina Jerabkova[SUP] 1 [/SUP], Jakub Mikes[SUP] 1 [/SUP], Frantisek Duska[SUP] 1 [/SUP], Ladislav Dusek[SUP] 6 [/SUP], Martin Balik[SUP] 7 [/SUP]
Affiliations
The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 µmol/l in patients on remdesivir decreased equally to controls (- 6 (- 20; 9) vs. - 8 (- 24; 2) µmol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr ≥ 150 µmol/l (- 57 (- 129; - 15) µmol/l for remdesivir group vs. - 65 (- 111; - 7) µmol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (- 2; 5) mmol/l vs. 0 (- 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT.
Keywords: Intensive care; Liver function tests; Remdesivir; Renal function; SARS-CoV-2; Viral load.
. 2025 Jul 1;15(1):20900.
doi: 10.1038/s41598-025-05541-9. The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load
Petr Waldauf[SUP] 1 [/SUP], Ivana Jurisinova[SUP] 2 [/SUP], Eva Svobodova[SUP] 2 [/SUP], Michaela Diblickova[SUP] 2 [/SUP], Tomas Tencer[SUP] 1 [/SUP], Jan Zavora[SUP] 3 4 [/SUP], Gabriela Smela[SUP] 3 [/SUP], Lenka Kupidlovska[SUP] 3 [/SUP], Vaclava Adamkova[SUP] 3 [/SUP], Marta Fridrichova[SUP] 5 [/SUP], Karolina Jerabkova[SUP] 1 [/SUP], Jakub Mikes[SUP] 1 [/SUP], Frantisek Duska[SUP] 1 [/SUP], Ladislav Dusek[SUP] 6 [/SUP], Martin Balik[SUP] 7 [/SUP]
Affiliations
- PMID: 40594535
- PMCID: PMC12214511
- DOI: 10.1038/s41598-025-05541-9
The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 µmol/l in patients on remdesivir decreased equally to controls (- 6 (- 20; 9) vs. - 8 (- 24; 2) µmol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr ≥ 150 µmol/l (- 57 (- 129; - 15) µmol/l for remdesivir group vs. - 65 (- 111; - 7) µmol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (- 2; 5) mmol/l vs. 0 (- 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT.
Keywords: Intensive care; Liver function tests; Remdesivir; Renal function; SARS-CoV-2; Viral load.